v3.26.1
Capital - Schedule of Share Capital Information (Detail)
€ / shares in Units, $ in Thousands, € in Millions
 12 Months Ended
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2025
EUR (€)
€ / shares
shares
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2024
€ / shares
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2023
€ / shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2022
€ / shares
Disclosure of classes of share capital [line items]                
Beginning balance $ 131,033   $ 84,695   $ 125,941      
Balance at beginning, Number of shares | shares 100,093,873 100,093,873 71,751,201   45,675,968      
Capital increase of Cellectis     $ 140,000   $ 69,985      
Capital increase by issuance of preference shares | shares     28,000,000          
Transaction costs related to capital increase     $ (207)          
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount $ 33   $ 0   $ 9      
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, shares | shares 245,568 [1] 245,568 [1] 342,672   167,433      
Non-cash stock-based compensation expense $ 6,110   $ 3,167   $ 9,092      
Other movements 11   (79)   (187)      
Balance at end of year $ 75,901   $ 131,033   $ 84,695   $ 125,941  
Balance at end, Number of shares | shares 100,339,441 100,339,441 100,093,873   71,751,201   45,675,968  
Nominal value | € / shares   € 0.05   € 0.05   € 0.05   € 0.05
Preferrence Shares [Member]                
Disclosure of classes of share capital [line items]                
Balance at beginning, Number of shares | shares     0          
Capital increase by issuance of preference shares | shares         25,907,800      
Balance at end, Number of shares | shares         0      
Share Capital Issued Capital [member]                
Disclosure of classes of share capital [line items]                
Beginning balance $ 5,889   $ 4,365   $ 2,955      
Capital increase of Cellectis     1,505          
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount 14 [1]   19   9      
Balance at end of year 5,903   5,889   4,365   $ 2,955  
Share Capital Issued Capital [member] | Preferrence Shares [Member]                
Disclosure of classes of share capital [line items]                
Capital increase of Cellectis     1,505   1,401      
Premiums Related to Share Capital [member]                
Disclosure of classes of share capital [line items]                
Beginning balance 494,288   522,785   583,122      
Allocation of prior period loss (62,999) [2] € (58.2) (112,911)          
Capital increase of Cellectis     138,495   68,584      
Transaction costs related to capital increase     (207)   (2,049)   (600)  
Derecognition of AZ derivative     (56,970)          
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount 36 [1]   9          
Non-cash stock-based compensation expense 6,110   3,167   7,086      
Other movements 11   (79)   (133,958)      
Balance at end of year $ 437,445   $ 494,288   $ 522,785   $ 583,122  
[1] During the year ended December 31, 2025, 245,568 ordinary shares were issued to the benefit of Company's employees related to the free shares plans which met vesting conditions and exercised stock options.
[2] The standalone statutory loss for the year ended December 31, 2024 of the parent company was allocated to premiums related to share capital for 58.2 million euros or approximately $63.0 million following the decision of the Annual General Meeting of shareholders which took place on June 26, 2025. The difference between this standalone statutory loss of the parent company and the consolidated net loss was allocated to retained deficit for $26.2 million.